The stock price of Novavax, Inc (NASDAQ: NVAX) has plunged by -5.27 when compared to previous closing price of 8.28, but the company has seen a -9.84% decline in its stock price over the last five trading sessions. zacks.com reported 2024-12-24 that Recently, Zacks.com users have been paying close attention to Novavax (NVAX). This makes it worthwhile to examine what the stock has in store.
Is It Worth Investing in Novavax, Inc (NASDAQ: NVAX) Right Now?
The 36-month beta value for NVAX is also noteworthy at 2.05. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”
The public float for NVAX is 153.00M, and at present, short sellers hold a 25.59% of that float. The average trading volume of NVAX on December 30, 2024 was 5.42M shares.
NVAX’s Market Performance
The stock of Novavax, Inc (NVAX) has seen a -9.84% decrease in the past week, with a -9.00% drop in the past month, and a -37.90% fall in the past quarter. The volatility ratio for the week is 4.35%, and the volatility levels for the past 30 days are at 5.28% for NVAX. The simple moving average for the past 20 days is -9.58% for NVAX’s stock, with a -25.92% simple moving average for the past 200 days.
Analysts’ Opinion of NVAX
Many brokerage firms have already submitted their reports for NVAX stocks, with JP Morgan repeating the rating for NVAX by listing it as a “Underweight.” The predicted price for NVAX in the upcoming period, according to JP Morgan is $8 based on the research report published on July 30, 2024 of the current year 2024.
BofA Securities gave a rating of “Neutral” to NVAX, setting the target price at $12 in the report published on May 10th of the current year.
NVAX Trading at -11.65% from the 50-Day Moving Average
After a stumble in the market that brought NVAX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.13% of loss for the given period.
Volatility was left at 5.28%, however, over the last 30 days, the volatility rate increased by 4.35%, as shares sank -10.07% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.23% lower at present.
During the last 5 trading sessions, NVAX fell by -9.87%, which changed the moving average for the period of 200-days by +57.46% in comparison to the 20-day moving average, which settled at $8.67. In addition, Novavax, Inc saw 63.41% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NVAX starting from YOUNG JAMES F, who proposed sale 10,000 shares at the price of $8.48 back on Dec 24 ’24. After this action, YOUNG JAMES F now owns shares of Novavax, Inc, valued at $84,800 using the latest closing price.
Rachel K. King, the Board Member of Novavax, Inc, proposed sale 4,150 shares at $9.00 during a trade that took place back on Dec 13 ’24, which means that Rachel K. King is holding shares at $37,350 based on the most recent closing price.
Stock Fundamentals for NVAX
Current profitability levels for the company are sitting at:
- -0.33 for the present operating margin
- 0.67 for the gross margin
The net margin for Novavax, Inc stands at -0.32. The total capital return value is set at -0.56.
Based on Novavax, Inc (NVAX), the company’s capital structure generated -0.47 points at debt to capital in total, while cash flow to debt ratio is standing at -0.54. The debt to equity ratio resting at -0.32. The interest coverage ratio of the stock is -17.78.
Currently, EBITDA for the company is -487.39 million with net debt to EBITDA at 1.57. When we switch over and look at the enterprise to sales, we see a ratio of 1.03. The receivables turnover for the company is 9.32for trailing twelve months and the total asset turnover is 0.52. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.93.
Conclusion
In summary, Novavax, Inc (NVAX) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
